The number of bariatric surgeries performed for weight loss has declined as prescriptions for GLP-1 medications like Ozempic, Wegovy, and Mounjaro skyrocketed, according to a new study published by Loyola Medicine. Researchers attribute the drop to the growing availability, accessibility, and perceived effectiveness of these injectable drugs, which have gained widespread attention for promoting substantial weight loss. The study highlights a shift in how patients and doctors approach weight management, moving away from surgical interventions toward pharmaceutical options.

Bariatric surgery, once the primary treatment for severe obesity, has long been regarded as the most effective long-term solution for sustained weight loss. Procedures such as gastric bypass and sleeve gastrectomy remain highly effective, with success rates often exceeding 60% for major weight loss over five years. However, the rise of GLP-1 receptor agonists—drugs that mimic the hormone glucagon-like peptide-1 to regulate appetite and blood sugar—has introduced a competitive alternative. These medications are now prescribed not only for diabetes but also for chronic weight management in patients with obesity or overweight conditions.

The decline in surgeries coincides with expanded insurance coverage and manufacturer discounts for GLP-1 drugs, making them more affordable and accessible. According to the study, the number of bariatric procedures dropped by approximately 10% in 2023 compared to 2022, while prescriptions for GLP-1 medications increased by nearly 50% over the same period. This trend underscores a broader transformation in obesity care driven by both medical innovation and consumer demand.

Medical experts emphasize that both bariatric surgery and GLP-1 drugs have valid roles in weight loss treatment, but their suitability depends on individual health profiles, goals, and risk tolerance. Dr. John Morton, a bariatric surgeon at Yale School of Medicine, noted that while surgery offers rapid and durable results, it carries surgical risks and requires lifelong dietary adjustments. GLP-1 medications, in contrast, provide gradual weight loss with fewer immediate complications but often require long-term use to maintain benefits.

How GLP-1 Drugs Compare to Bariatric Surgery

GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have shown average weight loss of 15–20% over 68–72 weeks in clinical trials, compared to 25–30% for bariatric surgery over the same period. However, patients using medications may regain weight after stopping treatment, whereas surgery tends to produce more permanent changes in gut anatomy and metabolism. The study found that nearly 60% of patients who started GLP-1 drugs discontinued them within a year due to side effects or cost, highlighting challenges in long-term adherence.

Despite the drop in surgeries, bariatric procedures remain a critical option for patients with severe obesity or obesity-related conditions such as type 2 diabetes or sleep apnea. Laparoscopic techniques have reduced recovery times to as little as two weeks, lowering barriers to surgery. The American Society for Metabolic and Bariatric Surgery reports that over 250,000 bariatric procedures were performed in the U.S. in 2022, though the number continues to trend downward as drug-based therapies gain ground.

What’s Next for Weight Loss Treatment

The obesity treatment landscape is rapidly evolving, with new GLP-1 formulations, combination therapies, and even oral alternatives in development. Companies are investing heavily in next-generation drugs aimed at improving efficacy and reducing side effects like nausea and constipation. Meanwhile, bariatric surgeons are exploring hybrid approaches, such as combining minimally invasive procedures with short-term medication use to optimize outcomes.

For patients, the message is clear: there is no one-size-fits-all solution. The decision between surgery and medication should be made in consultation with a healthcare provider, considering factors like BMI, comorbidities, lifestyle, and personal preferences. As both fields advance, the focus remains on improving long-term health outcomes and reducing obesity-related complications nationwide.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 08:58 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #weight-loss-surgeries · #decline · #use-skyrockets

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O Brasil, que já foi líder global em cirurgias bariátricas, agora vê uma queda acentuada nos procedimentos enquanto os medicamentos à base de GLP-1, como Ozempic e Wegovy, dominam a busca por perda de peso. Dados recentes revelam que o número de cirurgias de redução de estômago caiu pela metade em dois anos, refletindo uma mudança radical nos hábitos de tratamento da obesidade no país e no mundo.

A popularidade dos agonistas do GLP-1 não é mera coincidência: esses medicamentos, originalmente desenvolvidos para diabetes, se mostraram altamente eficazes no controle de peso, com efeitos colaterais menos agressivos do que os procedimentos cirúrgicos em muitos casos. No Brasil, onde a obesidade atinge mais de 22% da população adulta segundo o Ministério da Saúde, a opção farmacológica surge como uma alternativa mais acessível e menos invasiva, embora com custo elevado e disponibilidade limitada pelo SUS. Especialistas alertam, no entanto, que a substituição repentina das cirurgias pelos medicamentos exige cautela, pois nem todos os pacientes respondem da mesma forma e os efeitos a longo prazo ainda são estudados.

A tendência levanta questões sobre o futuro do tratamento da obesidade no país, com o sistema de saúde precisando se adaptar rapidamente para equilibrar inovação e acesso igualitário.

🇪🇸 Resumen en Español

La popularidad de los fármacos agonistas del GLP-1 como Ozempic y Wegovy ha provocado un notable descenso en las cirugías bariátricas, una tendencia que refleja un cambio radical en la lucha contra la obesidad. Según los últimos datos disponibles, el uso de estos medicamentos se ha disparado en los últimos años, desplazando en parte a las intervenciones quirúrgicas como opción preferida para perder peso.

Este giro en las estrategias médicas no solo subraya la creciente influencia de los tratamientos farmacológicos en la salud pública, sino que también plantea preguntas sobre su accesibilidad, efectos a largo plazo y sostenibilidad económica. Para millones de hispanohablantes que padecen obesidad o sobrepeso, la disponibilidad y el coste de estos fármacos —muchos de ellos aún no cubiertos por sistemas públicos de salud— pueden determinar si esta alternativa se convierte en una solución viable o en un privilegio para unos pocos. Además, mientras la cirugía bariátrica sigue siendo una opción con resultados demostrados para casos graves, la dependencia de medicamentos como Wegovy exige un debate sobre cómo equilibrar innovación, equidad y evidencia científica en el abordaje de una epidemia global.